Form 4: Vaxcyte Officer Dhaliwal Boosts Equity Holdings

Vaxcyte's Chief Technical Operations Officer, Harpreet S. Dhaliwal, reported significant equity awards including restricted stock units and stock options.

Summary

• Harpreet S. Dhaliwal, Chief Technical Operations Officer of Vaxcyte, Inc. (PCVX), reported transactions involving the company's common stock and stock options.
• On February 26, 2026, Dhaliwal acquired 53,409 shares of Common Stock underlying restricted stock units (RSUs) at a price of $0.
• Following this acquisition, Dhaliwal's direct beneficial ownership of Common Stock was 77,337 shares.
• Also on February 26, 2026, Dhaliwal acquired stock options for 46,424 shares of Common Stock with an exercise price of $60.
• On February 28, 2026, 292 shares of Common Stock were disposed of at $61.98 to cover tax withholding obligations related to RSU vesting, reducing beneficial ownership to 77,045 shares.
• On March 2, 2026, an additional 465 shares of Common Stock were disposed of at $61.98 for tax withholding, resulting in a final beneficial ownership of 76,580 shares of Common Stock.
• The RSUs vest as to 1/4 of the shares on September 7, 2026, and 1/8 every six months thereafter, contingent on continuous service.
• The stock options vest as to 1/48 of the shares on March 26, 2026, and 1/48 monthly thereafter, contingent on continuous service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices that align management incentives with shareholder value, without indicating any immediate operational or financial shifts.

Positives

• The Chief Technical Operations Officer received a significant grant of 53,409 restricted stock units (RSUs) and 46,424 stock options, aligning executive interests with shareholder value.
• The transactions were made pursuant to a Rule 10b5-1 plan, indicating pre-planned equity management.

Negatives

• A total of 757 shares of Common Stock were disposed of to cover tax withholding obligations, which is a routine event but represents a reduction in direct equity holdings.

Risks

• The vesting of both RSUs and stock options is contingent upon the reporting person's continuous service with the Issuer through each vesting date, posing a risk to full realization if employment ceases.

Future Outlook

The future outlook for the reporting person's equity holdings is tied to the vesting schedules of the granted RSUs and stock options, which extend through September 2026 and March 2026 (initial vesting) and beyond, contingent on continuous service.

Industry Context

StockSavvy.ai notes that equity grants to key executives like a Chief Technical Operations Officer are standard practice in the biotechnology and pharmaceutical industries, serving to attract, retain, and incentivize talent. These grants align executive performance with long-term company success and shareholder interests, a common strategy among peers in the competitive life sciences sector.

Comparison to Industry Standards

• The structure of RSU and stock option grants with multi-year vesting schedules is consistent with compensation practices observed at comparable biotech companies such as Moderna, BioNTech, and Regeneron, which often use long-term equity incentives to retain key scientific and operational leadership.
• The use of a Rule 10b5-1 plan for these transactions is a standard corporate governance practice, enhancing transparency and mitigating concerns about insider trading, aligning with best practices seen across the S&P 500.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the Chief Technical Operations Officer's financial interests with the long-term performance of the company, potentially fostering greater commitment to value creation.
• Employees: The compensation structure for a key executive may serve as a benchmark or motivator for other employees, particularly those in leadership or technical roles.

Next Steps

• Continued vesting of 53,409 restricted stock units, with the first 1/4 vesting on September 7, 2026, and 1/8 every six months thereafter.
• Continued vesting of 46,424 stock options, with the first 1/48 vesting on March 26, 2026, and 1/48 monthly thereafter.

Key Dates

Keywords

Vaxcyte, PCVX, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Executive Compensation, Equity Grant, Rule 10b5-1